Overview
Artios Pharma is a clinical-stage biopharmaceutical company developing first-in-class DNA Damage Response (DDR) inhibitors for hard-to-treat cancers. Its pipeline includes ATR inhibitor alnodesertib in clinical trials for pancreatic and colorectal cancers, DNA polymerase theta (Polθ) inhibitor ART6043 advancing to phase 2 for BRCA-mutant breast cancer, and preclinical DDRi-ADC candidates. The company leverages its DcoDeR platform and partnerships to target DDR pathways, overcoming resistance to therapies like PARP inhibitors.
Frequently asked questions
- What is Artios Pharma's main therapeutic focus?
- Artios specializes in DNA Damage Response (DDR) inhibitors targeting cancer cells' DNA repair mechanisms, including ATR inhibitor alnodesertib and Polθ inhibitor ART6043 for solid tumors like pancreatic, colorectal, and breast cancers.
- What stage are Artios' lead programs in?
- Alnodesertib (ATR inhibitor) is in clinical trials, expanding to second-line pancreatic and third-line colorectal cancers; ART6043 (Polθ inhibitor) showed early data and plans phase 2 in BRCA-mutant breast cancer; preclinical DDRi-ADCs are in development.
- Where is Artios Pharma located and what are its key partnerships?
- Headquartered in Cambridge, UK, and New York, USA, with a partnership with Cancer Research Technology (CRT) of Cancer Research UK for DDR programs.